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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• The dominant health economic units upon which new
treatment funding decisions are made are the
incremental cost per life year gained (LYG) or the cost
per quality-adjusted life year (QALY) gained.
• Neither of these units modifies the amount of health
gained, by the amount of health patients would have
had if they had not been given the treatment under
consideration, which may unfairly undervalue the
treatments for poor prognosis conditions.
• How certain patients make decisions about their own
treatment has previously been explored, but not how
they, or doctors, would allocate hypothetical resource
within a healthcare system given information on
disease-treatment scenarios’ prognoses with and
without treatment.
WHAT THIS STUDY ADDS
• Information on prognosis without treatment is used
within the resource allocation strategies of many
doctors and most patients.
• Individuals use this information in a variety of different
ways and a single dominant strategy for quantitative
modification of health units is not apparent.
• Information on prognosis without treatment, or
prognosis with standard treatment, is available from the
control arm of randomized controlled clinical trials and
should be used qualitatively to facilitate
decision-making around the second inflexion point on
cost per QALY/LYG acceptability curves.
AIMS
Health economic assessments increasingly contribute to funding decisions on
new treatments. Treatments for many poor prognosis conditions perform badly
in such assessments because of high costs and modest effects on survival. We
aimed to determine whether underlying shortness of prognosis should also be
considered as a modifier in such assessments.
METHODS
Two hundred and eighty-three doctors and 201 oncology patients were asked
to allocate treatment resource between hypothetical patients with unspecified
life-shortening diseases. The prognoses with and without treatment were varied
such that consistent use of one of four potential allocation strategies could be
deduced: life years gained (LYGs) – which did not incorporate prognosis without
treatment information; percentage increase in life years (PILY); life expectancy
with treatment (LEWT) or immediate risk of death (IRD).
RESULTS
Random choices were rare; 47% and 64% of doctors and patients, respectively,
used prognosis without treatment in their strategies; while 50% and 32%,
respectively, used pure LYG-based strategies. Ranking orders were
LYG > PILY > IRD > LEWT (doctors) and LEWT > LYG > IRD > PILY (patients). When
LYG information alone could not be used, 76% of doctors prioritized shorter
prognoses, compared with 45% of patients.
CONCLUSIONS
Information on prognosis without treatment is used within the resource
allocation strategies of many doctors and most patients, and should be
considered as a qualitative modifier during the health economic assessments of
new treatments for life-shortening diseases. A single dominant strategy
incorporating this information for any quantitative modification of health units
is not apparent.
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Introduction
Within recent years cost-effectiveness has been intro-
duced as an additional hurdle for new drugs to overcome,
before they are recommended for resource allocation
within a growing number of healthcare systems [1, 2].
Within the UK, the two predominant organizations
making these recommendations are the National Institute
for Clinical Excellence (NICE) in England and Wales, and
the Scottish Medicines Consortium (SMC) in Scotland. The
unit values upon which such organizations base their
health economic assessments, for each indication of a
drug, are usually either the incremental cost per life year
gained (LYG) for life-shortening conditions or, where avail-
able, the cost per quality-adjusted life year (QALY) gained.
As small additional increases in survival for life-shortening
conditions conceivably could be very important to those
who have a short time left to live, it is noteworthy that
neither of these units modifies the amount of health
gained, by the amount of health the patients would have
had if they had not been given the treatment [3]. Conse-
quently, treatments producing only modest improve-
ments in the survival of short prognosis conditions, such
as advanced cancer or severe heart failure, may be under-
valued by these measures. Although absolute cost per
QALY thresholds for acceptance/rejection are not
employed, a sigmoidal relationship between increasing
cost per QALY and the probability of a technology being
rejected is recognized [4]. The upper inflexion point of
such a curve, beyond which a technology is unlikely to be
approved in the UK currently lies within the £25 000–
£35 000 per QALY range. Within this range NICE has stated
that a number of additional factors beyond the cost per
QALY are (or should be) considered to facilitate the
decision-making process. These factors include the ‘inno-
vative nature of the technology’ and the ‘particular fea-
tures of the condition and population using the
technology’. ‘Particular features’ explicitly incorporates
‘special considerations of equity’ with many of NICE’s
judgements underpinned by the assumption that a ‘QALY
is a QALY is a QALY’, i.e. that the weight given to a QALY
should be the same regardless of the beneficiary’s age,
sex, social role or deprivation, how many QALYs they have
‘previously enjoyed’ or are in ‘prospect of enjoying’ [4]. It is
the last of these points that we address here, with regard
to life-shortening conditions. Prognosis without treatment
seemed to inform the choices made in an earlier pilot
study in which respondents were asked to choose which
one of three hypothetical patients with life-shortening
conditions to treat [3]. To explore in more detail the
importance of underlying prognosis without treatment,
the three commonest resource allocation strategies incor-
porating information on prognosis without treatment,
described by the respondents in the pilot study, were
compared quantitatively to the current health economic
standard of LYGs (which does not incorporate this infor-
mation). Decision patterns of doctors and oncology
patients were captured, when they were placed in the
position of resource-allocators and asked to distribute
treatment resource between a series of hypothetical
patients whose prognoses from life-shortening diseases
and gains from a novel treatment varied. The hypothetical
patients and their benefits from treatment, in theory,
being representative of the results of phase III clinical
studies of different novel treatments on different disease
types used as the basis for NICE and SMC decision-making
[3].
Methods
A previous qualitative pilot study of doctors, nurses and
medical secretaries determined the dominant resource-
allocation strategies involving prognosis without treat-
ment to compare against the standard LYG-based
strategy (Table 1) [3]. A deductive questionnaire was
developed for assessing quantitatively between these
four potential resource-allocation strategies (Figure 1). It
was explained to respondents, both verbally and in
writing that:
‘There are two hypothetical patients each with a
disease that they will eventually die from, but they will be
well until they die.You are not told what the disease is, but
it could be something like AIDS, or a type of cancer.There is
a treatment for the disease that is not a cure, but whoever
you give it to will live a period of time longer and they will
be well during this extra time.There are no side-effects and
there is no inconvenience associated with the treatment,
but there is only enough of it to give it to one of the two
patients in each question and you have to decide which
one.You are not told anything about the patients’ personal
circumstances,such as their age,or sex,or whether they are
married or have children.Whatever you imagine about the
two patients, it is the same for both’.
Four questions then followed, each one asking the
respondent to choose between treating patients A and B,
Table 1
Potential resource allocation strategies when information is provided
on individuals’ prognosis without treatment and gain in lifetime from
treatment
Life years gained (LYGs) – treatment allocation to the individual/group
that gains the most extra lifetime from being treated
Immediate risk of death (IRD) – treatment allocation to the
individual/group that would die the soonest if not treated
Percentage increase in life years (PILY) – treatment allocation to the
individual/group that gains the greatest percentage increase in their
life expectancy from being treated
Life expectancy with treatment (LEWT) – treatment allocation to the
individual/group that has the greatest total life expectancy when
prognosis without treatment and gain in lifetime from treatment are
added together
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where the parameters of gain from treatment and progno-
sis without treatment differed. The answers given to the
first three questions separated out the four main resource
allocation strategies as follows:
Potential strategies
used: if chose A if chose B
In Q1: IRD LYG, LEWT, PILY
In Q2: LEWT LYG, IRD, PILY
In Q3: IRD, PILY LYG, LEWT
Consequently, assuming constancy of method across a
narrow range of prognoses without treatment and gains in
lifetime from treatment, and that no other relevant strate-
gies existed and cosegregated, an overall resource-
allocation strategy for the respondent could be deduced
by looking for the one strategy that followed all choices.
The answers to Q1, Q2 and Q3, in order, offered eight pos-
sible outcomes and deductions:
AAA = no discernible strategy
AAB = no discernible strategy
ABB = no discernible strategy
BBB = lYG-based strategy
ABA = IRD-based strategy
BAB = LEWT-based strategy
BAA = no discernible strategy
BBA = PILY-based strategy
A fourth question, in which the gain in lifetime from
treatment was constant for both patients, was added soon
after study commencement, to address the role of progno-
sis without treatment as a potential second-tier resource
allocation strategy when LYG-based approaches were not
tenable as the primary strategy.
The questionnaire was administered to both doctors, as
the potential allocators of resource, and patients attending
the Edinburgh Cancer Centre (ECC), as the potential recipi-
ents of resource allocation decisions pertaining to life-
shortening conditions.
Using a two-group continuity-corrected chi-squared
test,a sample size of 175 per group was calculated as being
sufficient to detect a 20% difference in strategy prefer-
ences, within and between groups, with 80% power at the
5% significance level (two-sided test). A separate subgroup
of medical and clinical (radiation) oncologists, aiming for at
least 50 individuals, was also recruited to assess whether
there was any evidence that doctors with day-to-day expe-
rience of life-shortening diseases would give different
responses from doctors in general.No randomization steps
were involved. Postal returns were permitted. Because of
delay in some postal returns, final numbers of completed
questionnaires exceeded the original recruitment targets.
On completion, groups (excluding responses with no
discernible strategy) were initially compared using chi-
squared or Fisher’s exact tests (depending on the number
of events in each cell). For those that showed a statistically
significant difference (P < 0.05), each strategy choice was
then compared with the same strategy choice between
groups using a binomial test of proportions.
Results
Three hundred and thirteen doctors were approached, of
whom 283 completed the questionnaire (33 question-
naires containing only questions 1–3, 250 questionnaires
containing questions 1–4). Of these, 84 were oncologists
(medical or clinical) of specialist registrar/staff grade or
higher, 57 of whom completed the questionnaire (all con-
taining questions 1–4). Two hundred and ninety-eight
patients were approached, of whom 201 completed the
questionnaire (26 questionnaires containing only ques-
tions 1–3, 175 containing questions 1–4).
There was no evidence of a framing effect from ques-
tion 4, with the proportions of doctors and patients
Ring A or B for each of the four questions 
Question 1 
BA
Total lifetime if NOT treated
EXTRA lifetime from treatment 3 months 9 months
3 months 6 months
6 months 15 months
3 months 6 months
9 months 3 months
12 months 9 months
6 months 9 months
3 months 6 months
9 months 15 months
3 months 3 months
3 months 6 months
6 months 9 months
Total lifetime if  TREATED
Question 2: 
BA
Total lifetime if NOT treated
EXTRA lifetime from treatment
Total lifetime if  TREATED
Question 3: 
BA
Total lifetime if NOT treated
EXTRA lifetime from treatment
Total lifetime if  TREATED
Question 4: 
BA
Total lifetime if NOT treated
EXTRA lifetime from treatment
Total lifetime if  TREATED
Figure 1
Resource allocation questionnaire. The clinical scenario on which the
questions are based is described in the methods section
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answering A or B to each of questions 1–3 being similar
regardless of whether the fourth question was present or
absent (data not shown). Data from all questions 1–3,
regardless of the presence or absence of question 4 within
the same questionnaire, were combined in the analysis of
each respondent group. The resource allocation strategies
deduced from the answers given to questions 1–3 for
doctors and patients, and their answers to question 4, are
shown in Table 2. Oncologists and nononcology doctors
produced identical rankings, but differed in terms of the
proportions choosing LYG-based (64% vs. 49%, respec-
tively, P = 0.031) and LEWT-based strategies (0% vs. 9%,
respectively, P < 0.001). The patients differed from the
doctors (all doctors combined) for both the strategies
deduced from questions 1–3 (chi-squared P < 0.001) and
for question 4 (chi-squared P < 0.001). Using a binomial
test of proportions, there was a statistically significant dif-
ference between doctors and patients for each specific
resource allocation strategy (P < 0.001), except IRD
(P = 0.102).
Discussion
Healthcare resource allocation bodies, commonly base
their health economic decision-making on the cost per LYG
or, per QALY, of each specific therapeutic interventional
scenario. Prognosis without treatment (or ‘prognosis with
standard treatment’, as opposed to that with the new
therapeutic intervention under consideration) seemed to
inform respondent treatment-allocation choices made in
an earlier pilot study [3]. The same broad concept,
expressed as ‘urgency of need’ has also been argued as a
relevant factor in the allocation of a limited supply of
donor organs to potential transplant recipients, although
there are certain differences, e.g. the assumption that treat-
ment equates to ‘cure’ in many transplant cases [5, 6].
Within the confines of the deductive questionnaire
employed in the present study, for both doctors and
patients the number of respondents without discernible
strategies was proportionally very low (<4% in all groups),
implying that the choices made were rarely random.
Random choice would have produced responses without a
discernible strategy in 50% of cases. Non-oncology doctors
and oncologists produced identical rankings and only
minor differences in their proportional splits in terms of
their preferred resource allocation strategy:
LYG > PILY > IRD > LEWT (Table 2), suggesting that precise
medical background or particular exposure to life-
shortening conditions has little influence on the strategy
employed by doctors. Within the study costs were not
mentioned, and it does not seem unreasonable to assume
that the costs from the perspective of the decision-maker
were therefore equivalent, or equally irrelevant, for each
choice. Since quality of life both on and off treatment was
explicitly stated as good (i.e. fixed) within the study, these
results provide the first approximate validation by doctors
of cost per LYG or cost per QALY as the dominant resource
allocation strategies employed by bodies such as NICE and
the SMC.
Of the other strategies explored in this study, PILY- and
IRD-based strategies are similar in that they both empha-
size value in relation to the shortness of the prognosis
without treatment (in contrast to a LEWT-based strategy,
which places greater value on longer prognosis without
treatment). While the predominance of LYG-based strate-
gies among doctors may initially appear to negate the
earlier suggestion that prognosis without treatment is rel-
evant to resource allocation, when the proportions choos-
ing PILY- or IRD-based strategies were combined, a good
case for providing information on shortness of prognosis
regardless of LYG was apparent with 40% (112/283) prefer-
ring a strategy employing this information compared with
50% (142/283) preferring a strategy that did not. In addi-
tion, in question 4, when the LYGs associated with treat-
ment were the same for each choice, there was a clear
preference for allocating resource to the individual with
the shortest prognosis without treatment (Table 2). The
Table 2
Resource allocation strategies of doctors and oncology patients within the questionnaire
Doctors (total) Doctors (nononcologists) Doctors (oncologists) Oncology patients
Deduced resource allocation strategy (questions 1–3):
Total = 283 Total = 226 Total = 57 Total = 201
LYG 142 (50%) 106 (47%) 36 (63%) 65 (32%)
IRD 35 (12%) 27 (12%) 8 (14%) 35 (17%)
PILY 77 (27%) 65 (29%) 12 (21%) 21 (10%)
LEWT 20 (7%) 20 (9%) 0 (0%) 73 (36%)
No discernible strategy 9 (3%) 8 (4%) 1 (2%) 7 (4%)
Allocation when LYGs equal between patients (question 4):
Total = 175 Total = 249 Total = 193 Total = 56
A – to shorter prognosis 188 (76%) 142 (74%) 46 (82%) 79 (45%)
B – to longer prognosis 61 (24%) 51 (26%) 10 (18%) 96 (55%)
Impact of prognosis without treatment
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very low percentage of doctors favouring LEWT-based
resource allocation strategies, particularly among oncolo-
gists, also supports this view.
Although doctors and other healthcare professionals
are traditionally the individuals most associated with
healthcare resource allocation, there is a move to involve
the consumers of healthcare in policy making [7, 8].To this
end we solicited the views of patients attending the ECC as
examples of those with experience of life-shortening dis-
eases. The patients’ resource allocation decision-making
was very different from that of the doctors, both in terms of
ranking (LEWT > LYG > IRD > PILY) and proportional splits.
The most notable difference between the doctor and
patient groups was the prioritization by 36% of patients of
a strategy valuing length of overall survival with treatment
(LEWT-based strategy), apparently rating longer prog-
noses without treatment above shorter ones when allocat-
ing resource (Table 2). It is important to note that decision-
making about resource allocation to others is potentially
very different from personal choices about one’s own
treatment, an area that has previously been explored for
cancer patients to some extent [9]. Patients with advanced
cancer have been noted to be more likely to accept aggres-
sive treatment aimed at extending life if they believed they
had a high chance of surviving 6 months on standard
therapy, compared with those who believed they were
unlikely to survive 6 months, broadly in line with the prin-
ciples of LEWT-based resource allocation [9]. In question 4,
however, the patient group was fairly evenly split as to
whether they emphasized length or shortness of progno-
sis without treatment when LYGs were the same. We have
previously argued that a universally applied LEWT-based
strategy would not be tenable as a resource-allocation
strategy in health economic assessments, because of the
potential to underemphasize or ignore the impact of the
treatment under consideration [3]. Perhaps, despite the
questionnaire being worded in a non disease-specific
manner about allocating resource to others, rather than to
the respondents, some patients may have been voting for
the clinical state that they themselves would prefer,
valuing total prognosis absolutely, regardless of how the
different elements contributed to the overall figure.
Discrepancies between the decisions made by doctors
and by the public (rather than specifically by patients) have
been noted with respect to other resource allocation
issues, including donor organs for transplant and ‘do not
resuscitate’ orders [10, 11]. These discrepancies initially
raise issues about ensuring that all sides are fully informed
and the consequences of decisions made clear [10, 12].
Although the questionnaire employed in both the pilot
study and the present study did not constrain the diag-
noses of the hypothetical patients to any particular condi-
tion, questions also arise as to what extent the responses
from any patient group (in this example, oncology
patients) are generalizable to other patient groups (e.g.
those with other life-shortening diseases) or the general
public. Assuming that these issues can be adequately
addressed, the present study strongly suggests that prog-
nosis without treatment is important in many doctors’
and most patients’ resource allocation decision-making
(PILY + IRD + LEWT = 47% and 64%, respectively). On this
basis we reject the notion that a ‘QALY is a QALY is a QALY’
under the life-shortening conditions explored within this
study. However, a single dominant resource allocation
strategy, incorporating prognosis without treatment infor-
mation, suitable for quantitative use within health eco-
nomic assessments is not apparent and the continued use
of LYG-based strategies as the quantitative standard is sup-
ported [3]. Even when individuals use prognostic informa-
tion in a comparable manner (e.g. valuing shortness rather
than length of prognosis without treatment), they seem to
do so in subtly different ways.This suggests that prognosis
without treatment should instead be supplied primarily as
a qualitative facilitator of decision-making around the
second inflexion point on the cost per QALY acceptability
curve, in a manner akin to the way that information on
the ‘innovative nature’ of new technologies is already
employed [4]. Information on prognosis without treat-
ment, or prognosis with standard treatment, is freely avail-
able from the control arm of the randomized controlled
clinical trials already used as source data within existing
health economic assessment procedures. We would
support the consideration of data on prognosis without
treatment during the assessment of all new treatments for
life-shortening conditions, allowing the clinical and lay
members of resource allocation bodies to then weigh this
information alongside other available quantitative and
qualitative health economic modifiers as they see fit.
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